PacBio Increases IPO Target Amount to $230M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pacific Biosciences today amended its preliminary prospectus, increasing the amount it hopes to raise from its initial public offering to up to $230 million.

The company had said that the offering could raise as much as $200 million in its original Form S-1 filed in August.

The firm still has not priced its shares for the proposed IPO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.